MedTrace Logo

Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation

NCT02424370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 515

Last updated 2020-10-12

No results posted yet for this study

Summary

Transcutaneous trans-aortic valve replacement (TAVR) is now a common procedure to treat symptomatic aortic stenosis. Although as effective and safe as surgical aortic valve replacement, it is still restricted to high surgical risk patient who are frail. The aim of the TAVI-EVA is to identify geriatric biomarkers that may help to predict survival and functional recovery after TAVR

Conditions

  • Symptomatic Aortic Stenosis

Interventions

PROCEDURE

TAVR

Percutaneous aortic valve replacement

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Joël BELMIN, MD,PhD · Assistance Publique - Hôpitaux de Paris

  • Jean Philippe COLLET, MD,PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-09
Primary Completion
2018-09-18
Completion
2020-01-23

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02424370 on ClinicalTrials.gov